Back to Search Start Over

Novel Sars-Cov-2 Pandemic Transmission With Ongoing Antiviral Therapies And Vaccine Design

Authors :
Yameen, Muhammad
Sattar, Sara
Khalid, Ayesha
Aslam, Muhammad Aamir
Zafar, Nishat
Saeed, Muhammad Hassan
Arif, Muhammad Haseeb
Jahangeer, Muhammad
Qadeer, Azka
Hussain, Shoukat
Aamir, Muhammad
Mukhtar, Sania
Nasir, Huma
Shahzad, Asif
Source :
Postępy Mikrobiologii, Vol 60, Iss 1 (2021)
Publication Year :
2021
Publisher :
Walter de Gruyter GmbH, 2021.

Abstract

Starting from the end of 2019 the new SARs-CoV-2 virus, in the period of a few months, had spread to 210 countries and its territories. The Wuhan wild animal market, in Hubei province, China is considered the epicenter of this pandemic. WHO declared the name COVID-19 to designate the disease caused by the SARS-CoV-2 virus. It is the third coronavirus pandemic after SARS in 2002–2003 and MERS-CoV in 2012. Genome sequencing of this new COVID-19/SARS-CoV-2 virus shows slight genetic diversity when compared to other coronaviruses. Owing to its pathogenesis, and less known replication cycle, no universal antiviral treatment can be applied and vaccine preparation is still a larger challenge. The present article will highlight transmission, pandemic status, genetic diversity current antiviral therapy, and vaccine trials for COVID-19. 1. Introduction. 2. Pathogenesis of coronaviruses. 3. Genetic diversity. 4. Transmission. 5. Vaccination strategies against COVID-19. 6. In Process Vaccination strategies against COVID-19. 7. Lack of antiviral treatment and antiviral treatment studies. 8. Precautions. 9. Conclusions

Details

ISSN :
25453149
Volume :
60
Database :
OpenAIRE
Journal :
Postępy Mikrobiologii - Advancements of Microbiology
Accession number :
edsair.doi.dedup.....8aa19b25e19b8b02b92a8a8a9607cf70
Full Text :
https://doi.org/10.21307/pm-2021.60.1.02